buccal fentanyl

buccal fentanyl

an opioid analgesic.
indications This drug is used to treat breakthrough pain in cancer patients who are taking regularly scheduled doses of another opiate pain medication and who are tolerant to opiates.
contraindications Known intolerance or hypersensitivity to this drug or its components prohibits its use. This drug must not be used in the management of acute or postoperative pain.
adverse effects Adverse effects of this drug include dizziness, delirium, euphoria, lightheadedness, sedation, dysphoria, agitation, anxiety, confusion, headache, depression, bradycardia, hypotension, hypertension, facial flushing, chills, chest pain, dysrhythmias, blurred vision, miosis, nausea, vomiting, diarrhea, cramps, anorexia, constipation, dyspepsia, urinary retention, urgency, dysuria, frequency, oliguria, sweating, pruritus, rash, erythema, papules, asthenia, depressed cough, hypoventilation, dyspnea, hiccups, and apnea. Life-threatening side effects include cardiac arrest, respiratory depression, laryngospasm, and bronchospasm.
Mentioned in ?
References in periodicals archive ?
A warning about the buccal fentanyl formulation was issued in September 2007 (INTERNAL MEDICINE NEWS, Nov.
The new Pharmacor report Opportunities in Acute Pain finds that Endo Pharmaceuticals' immediate-release and extended-release formulations of oxymorphone -- Opana and Opana ER -- as well as Johnson & Johnson's IONSYS (fentanyl iontophoresis system) and Cephalon's Fentora (effervescent buccal fentanyl tablet) will help drive steady annual growth in the acute pain market during the 2005-2015 study period.
Generex Biotechnology Corporation , a leader in the area of buccal drug delivery, today announced that Health Canada has approved an Investigational New Drug (IND) application to commence clinical trials of buccal fentanyl for the treatment of pain.